[Pharmacokinetics of the new antitumor antibiotic reumycin in an experiment: the prediction of the human pharmacokinetic profiles].
The reumycin pharmacokinetics was studied with HPLC on Wistar rats after intravenous injection of the antibiotic in single doses of 2.5, 5 and 10 mg/kg and after its oral administration in single doses of 5 and 10 mg/kg. It was shown that the reumycin pharmacokinetics within the above dose ranges was nonlinear and within every dose could be described by a two-compartmental model. Its nonlinear nature might be associated with saturated binding of the antibiotic by the blood serum proteins. The absolute extent of the reumycin bioavailability after oral administration was 50 per cent. The variability of the reumycin cumulative renal excretion was due to bimodality of distribution of the parameter in the animals. Renal excretion of the intact antibiotic decreased from 35 to 20 per cent with increasing of the dose. The value of the reumycin half-life in humans was predicted (41-46 hours) with the pharmacokinetic animal scale-up.